Tumor-penetrating Peptide Conjugated and Doxorubicin Loaded T1-T2 Dual Mode MRI Contrast Agents Nanoparticles for Tumor Theranostics
The conventional chemotherapeutics could not be traced in vivo and provide timely feedback on the clinical effectiveness of drugs. Methods: In this study, a tumor-penetrating peptide RGERPPR (RGE) modified, Gd-DTPA conjugated, and doxorubicin (DOX) loaded Fe3O4@SiO2@mSiO2 nanoparticle drug delivery...
Saved in:
Published in | Theranostics Vol. 8; no. 1; pp. 92 - 108 |
---|---|
Main Authors | , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Sydney
Ivyspring International Publisher
01.01.2018
|
Subjects | |
Online Access | Get full text |
ISSN | 1838-7640 1838-7640 |
DOI | 10.7150/thno.21074 |
Cover
Loading…
Abstract | The conventional chemotherapeutics could not be traced in vivo and provide timely feedback on the clinical effectiveness of drugs. Methods: In this study, a tumor-penetrating peptide RGERPPR (RGE) modified, Gd-DTPA conjugated, and doxorubicin (DOX) loaded Fe3O4@SiO2@mSiO2 nanoparticle drug delivery system (Fe3O4@SiO2@mSiO2/DOX-(Gd-DTPA)-PEG-RGE NPs) was prepared for tumor theranostics. Results: The Fe3O4@SiO2@mSiO2/DOX-(Gd-DTPA)-PEG-RGE NPs showed a z-average hydrodynamic diameter of about 90 nm, and a pH-sensitive DOX release profile. The 3 T MRI results confirmed the relaxivity of the NPs (r1 = 6.13 mM-1S-1, r2 = 36.89 mM-1S-1). The in vitro cellular uptake and cytotoxicity assays on U87MG cells confirmed that the conjugation of RGERPPR played a significant role in increasing the cellular uptake and cytotoxicity of the NPs. The near-infrared fluorescence in vivo imaging results showed that the NPs could be significantly accumulated in the U87MG tumor tissue, which should result from the mediation of the tumor-penetrating peptide RGERPPR. The MRI results showed that the NPs offered a T1-T2 dual mode contrast imaging effect which would lead to a more precise diagnosis. Compared with unmodified NPs, the RGE-modified NPs showed significantly enhanced MR imaging signal in tumor tissue and antitumor effect, which should also be attributed to the tumor penetrating ability of RGERPPR peptide. Furthermore, the Hematoxylin and Eosin (H&E) staining and TUNEL assay proved that the NPs produced obvious cell apoptosis in tumor tissue. Conclusions: These results indicated that Fe3O4@SiO2@mSiO2/DOX-(Gd-DTPA)-PEG-RGE NPs are an effective targeted delivery system for tumor theranostics, and should have a potential value in the personalized treatment of tumor.The conventional chemotherapeutics could not be traced in vivo and provide timely feedback on the clinical effectiveness of drugs. Methods: In this study, a tumor-penetrating peptide RGERPPR (RGE) modified, Gd-DTPA conjugated, and doxorubicin (DOX) loaded Fe3O4@SiO2@mSiO2 nanoparticle drug delivery system (Fe3O4@SiO2@mSiO2/DOX-(Gd-DTPA)-PEG-RGE NPs) was prepared for tumor theranostics. Results: The Fe3O4@SiO2@mSiO2/DOX-(Gd-DTPA)-PEG-RGE NPs showed a z-average hydrodynamic diameter of about 90 nm, and a pH-sensitive DOX release profile. The 3 T MRI results confirmed the relaxivity of the NPs (r1 = 6.13 mM-1S-1, r2 = 36.89 mM-1S-1). The in vitro cellular uptake and cytotoxicity assays on U87MG cells confirmed that the conjugation of RGERPPR played a significant role in increasing the cellular uptake and cytotoxicity of the NPs. The near-infrared fluorescence in vivo imaging results showed that the NPs could be significantly accumulated in the U87MG tumor tissue, which should result from the mediation of the tumor-penetrating peptide RGERPPR. The MRI results showed that the NPs offered a T1-T2 dual mode contrast imaging effect which would lead to a more precise diagnosis. Compared with unmodified NPs, the RGE-modified NPs showed significantly enhanced MR imaging signal in tumor tissue and antitumor effect, which should also be attributed to the tumor penetrating ability of RGERPPR peptide. Furthermore, the Hematoxylin and Eosin (H&E) staining and TUNEL assay proved that the NPs produced obvious cell apoptosis in tumor tissue. Conclusions: These results indicated that Fe3O4@SiO2@mSiO2/DOX-(Gd-DTPA)-PEG-RGE NPs are an effective targeted delivery system for tumor theranostics, and should have a potential value in the personalized treatment of tumor. |
---|---|
AbstractList | The conventional chemotherapeutics could not be traced in vivo and provide timely feedback on the clinical effectiveness of drugs. Methods: In this study, a tumor-penetrating peptide RGERPPR (RGE) modified, Gd-DTPA conjugated, and doxorubicin (DOX) loaded Fe3O4@SiO2@mSiO2 nanoparticle drug delivery system (Fe3O4@SiO2@mSiO2/DOX-(Gd-DTPA)-PEG-RGE NPs) was prepared for tumor theranostics. Results: The Fe3O4@SiO2@mSiO2/DOX-(Gd-DTPA)-PEG-RGE NPs showed a z-average hydrodynamic diameter of about 90 nm, and a pH-sensitive DOX release profile. The 3 T MRI results confirmed the relaxivity of the NPs (r1 = 6.13 mM-1S-1, r2 = 36.89 mM-1S-1). The in vitro cellular uptake and cytotoxicity assays on U87MG cells confirmed that the conjugation of RGERPPR played a significant role in increasing the cellular uptake and cytotoxicity of the NPs. The near-infrared fluorescence in vivo imaging results showed that the NPs could be significantly accumulated in the U87MG tumor tissue, which should result from the mediation of the tumor-penetrating peptide RGERPPR. The MRI results showed that the NPs offered a T1-T2 dual mode contrast imaging effect which would lead to a more precise diagnosis. Compared with unmodified NPs, the RGE-modified NPs showed significantly enhanced MR imaging signal in tumor tissue and antitumor effect, which should also be attributed to the tumor penetrating ability of RGERPPR peptide. Furthermore, the Hematoxylin and Eosin (H&E) staining and TUNEL assay proved that the NPs produced obvious cell apoptosis in tumor tissue. Conclusions: These results indicated that Fe3O4@SiO2@mSiO2/DOX-(Gd-DTPA)-PEG-RGE NPs are an effective targeted delivery system for tumor theranostics, and should have a potential value in the personalized treatment of tumor.The conventional chemotherapeutics could not be traced in vivo and provide timely feedback on the clinical effectiveness of drugs. Methods: In this study, a tumor-penetrating peptide RGERPPR (RGE) modified, Gd-DTPA conjugated, and doxorubicin (DOX) loaded Fe3O4@SiO2@mSiO2 nanoparticle drug delivery system (Fe3O4@SiO2@mSiO2/DOX-(Gd-DTPA)-PEG-RGE NPs) was prepared for tumor theranostics. Results: The Fe3O4@SiO2@mSiO2/DOX-(Gd-DTPA)-PEG-RGE NPs showed a z-average hydrodynamic diameter of about 90 nm, and a pH-sensitive DOX release profile. The 3 T MRI results confirmed the relaxivity of the NPs (r1 = 6.13 mM-1S-1, r2 = 36.89 mM-1S-1). The in vitro cellular uptake and cytotoxicity assays on U87MG cells confirmed that the conjugation of RGERPPR played a significant role in increasing the cellular uptake and cytotoxicity of the NPs. The near-infrared fluorescence in vivo imaging results showed that the NPs could be significantly accumulated in the U87MG tumor tissue, which should result from the mediation of the tumor-penetrating peptide RGERPPR. The MRI results showed that the NPs offered a T1-T2 dual mode contrast imaging effect which would lead to a more precise diagnosis. Compared with unmodified NPs, the RGE-modified NPs showed significantly enhanced MR imaging signal in tumor tissue and antitumor effect, which should also be attributed to the tumor penetrating ability of RGERPPR peptide. Furthermore, the Hematoxylin and Eosin (H&E) staining and TUNEL assay proved that the NPs produced obvious cell apoptosis in tumor tissue. Conclusions: These results indicated that Fe3O4@SiO2@mSiO2/DOX-(Gd-DTPA)-PEG-RGE NPs are an effective targeted delivery system for tumor theranostics, and should have a potential value in the personalized treatment of tumor. The conventional chemotherapeutics could not be traced in vivo and provide timely feedback on the clinical effectiveness of drugs. Methods: In this study, a tumor-penetrating peptide RGERPPR (RGE) modified, Gd-DTPA conjugated, and doxorubicin (DOX) loaded Fe 3 O 4 @SiO 2 @mSiO 2 nanoparticle drug delivery system (Fe 3 O 4 @SiO 2 @mSiO 2 /DOX-(Gd-DTPA)-PEG-RGE NPs) was prepared for tumor theranostics. Results: The Fe 3 O 4 @SiO 2 @mSiO 2 /DOX-(Gd-DTPA)-PEG-RGE NPs showed a z-average hydrodynamic diameter of about 90 nm, and a pH-sensitive DOX release profile. The 3 T MRI results confirmed the relaxivity of the NPs (r 1 = 6.13 mM -1 S -1 , r 2 = 36.89 mM -1 S -1 ). The in vitro cellular uptake and cytotoxicity assays on U87MG cells confirmed that the conjugation of RGERPPR played a significant role in increasing the cellular uptake and cytotoxicity of the NPs. The near-infrared fluorescence in vivo imaging results showed that the NPs could be significantly accumulated in the U87MG tumor tissue, which should result from the mediation of the tumor-penetrating peptide RGERPPR. The MRI results showed that the NPs offered a T 1 -T 2 dual mode contrast imaging effect which would lead to a more precise diagnosis. Compared with unmodified NPs, the RGE-modified NPs showed significantly enhanced MR imaging signal in tumor tissue and antitumor effect, which should also be attributed to the tumor penetrating ability of RGERPPR peptide. Furthermore, the Hematoxylin and Eosin (H&E) staining and TUNEL assay proved that the NPs produced obvious cell apoptosis in tumor tissue. Conclusions: These results indicated that Fe 3 O 4 @SiO 2 @mSiO 2 /DOX-(Gd-DTPA)-PEG-RGE NPs are an effective targeted delivery system for tumor theranostics, and should have a potential value in the personalized treatment of tumor. |
Author | Gao, Lipeng Wang, Yiting Yu, Jing Zhou, Jinge Yan, Zhiqiang Liu, Yang Sun, Lei Wang, Jing Zhu, Jianzhong Yu, Lei Lu, Weiyue Peng, Hui |
AuthorAffiliation | 3 Department of Pharmaceutics, School of Pharmacy, Fudan University & Key Laboratory of Smart Drug Delivery, Fudan University, Ministry of Education, Shanghai 201203, China 1 Institute of Biomedical Engineering and Technology, Shanghai Engineering Research Center of Molecular Therapeutics and New Drug Development, School of Chemistry and Molecular Engineering, East China Normal University, Shanghai 200062, China 2 Key Laboratory of Polar Materials and Devices, Ministry of Education, School of Information Science and Technology, East China Normal University, Shanghai 200241, China |
AuthorAffiliation_xml | – name: 2 Key Laboratory of Polar Materials and Devices, Ministry of Education, School of Information Science and Technology, East China Normal University, Shanghai 200241, China – name: 1 Institute of Biomedical Engineering and Technology, Shanghai Engineering Research Center of Molecular Therapeutics and New Drug Development, School of Chemistry and Molecular Engineering, East China Normal University, Shanghai 200062, China – name: 3 Department of Pharmaceutics, School of Pharmacy, Fudan University & Key Laboratory of Smart Drug Delivery, Fudan University, Ministry of Education, Shanghai 201203, China |
Author_xml | – sequence: 1 givenname: Lipeng surname: Gao fullname: Gao, Lipeng – sequence: 2 givenname: Jing surname: Yu fullname: Yu, Jing – sequence: 3 givenname: Yang surname: Liu fullname: Liu, Yang – sequence: 4 givenname: Jinge surname: Zhou fullname: Zhou, Jinge – sequence: 5 givenname: Lei surname: Sun fullname: Sun, Lei – sequence: 6 givenname: Jing surname: Wang fullname: Wang, Jing – sequence: 7 givenname: Jianzhong surname: Zhu fullname: Zhu, Jianzhong – sequence: 8 givenname: Hui surname: Peng fullname: Peng, Hui – sequence: 9 givenname: Weiyue surname: Lu fullname: Lu, Weiyue – sequence: 10 givenname: Lei surname: Yu fullname: Yu, Lei – sequence: 11 givenname: Zhiqiang surname: Yan fullname: Yan, Zhiqiang – sequence: 12 givenname: Yiting surname: Wang fullname: Wang, Yiting |
BookMark | eNpVjk1P3DAQhq0KVJYtl_4CH7mE-jOOL5XQLrRIuwWh9Bx548muV1k72A6id3444eNA5zKjefQ-M6foyAcPCH2n5EJRSX7knQ8XjBIlvqAZrXhVqFKQo0_zCTpLaU-mEoRpqr-iE6aZJkrLGXqux0OIxQAecjTZ-S2-gyE7C3gR_H7cmgwWG2_xMjyFOG5c6zxeBWOndU2LmuHlaHq8DlNifX_zmppEKePLLfic8B_jw2Bidm0PCXch4reLuN5BnFCaQPqGjjvTJzj76HP09_qqXvwuVre_bhaXq2LPhcyFpVJxUyrodKV4Z0CXstTtRpaiolBWTFmz6VhrK2s0VKQjHWhqudCWCqIJn6Of795h3BzAtvD6at8M0R1M_NcE45r_iXe7ZhseG6kEFyWbBOcfghgeRki5ObjUQt8bD2FMDdUVZ1JqQfkLZXaAqA |
ContentType | Journal Article |
Copyright | Ivyspring International Publisher 2018 |
Copyright_xml | – notice: Ivyspring International Publisher 2018 |
DBID | 7X8 5PM |
DOI | 10.7150/thno.21074 |
DatabaseName | MEDLINE - Academic PubMed Central (Full Participant titles) |
DatabaseTitle | MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Engineering |
EISSN | 1838-7640 |
EndPage | 108 |
ExternalDocumentID | PMC5743462 |
GroupedDBID | --- 53G 5VS 7X8 ADBBV ADRAZ AENEX ALIPV ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL BCNDV DIK GROUPED_DOAJ HYE KQ8 M48 M~E O5R O5S OK1 PGMZT RPM 5PM |
ID | FETCH-LOGICAL-j345t-d1573a67ef9873fae96569cb56481e6827dabf2cd8da9e80f0fe91d349d140903 |
IEDL.DBID | M48 |
ISSN | 1838-7640 |
IngestDate | Thu Aug 21 14:12:22 EDT 2025 Fri Jul 11 12:27:18 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 1 |
Language | English |
License | This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-j345t-d1573a67ef9873fae96569cb56481e6827dabf2cd8da9e80f0fe91d349d140903 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Competing Interests: The authors have declared that no competing interest exists. |
OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.7150/thno.21074 |
PMID | 29290795 |
PQID | 1983255941 |
PQPubID | 23479 |
PageCount | 17 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_5743462 proquest_miscellaneous_1983255941 |
PublicationCentury | 2000 |
PublicationDate | 20180101 |
PublicationDateYYYYMMDD | 2018-01-01 |
PublicationDate_xml | – month: 01 year: 2018 text: 20180101 day: 01 |
PublicationDecade | 2010 |
PublicationPlace | Sydney |
PublicationPlace_xml | – name: Sydney |
PublicationTitle | Theranostics |
PublicationYear | 2018 |
Publisher | Ivyspring International Publisher |
Publisher_xml | – name: Ivyspring International Publisher |
SSID | ssj0000402919 |
Score | 2.450343 |
Snippet | The conventional chemotherapeutics could not be traced in vivo and provide timely feedback on the clinical effectiveness of drugs. Methods: In this study, a... The conventional chemotherapeutics could not be traced in vivo and provide timely feedback on the clinical effectiveness of drugs. Methods: In this study, a... |
SourceID | pubmedcentral proquest |
SourceType | Open Access Repository Aggregation Database |
StartPage | 92 |
SubjectTerms | Research Paper |
Title | Tumor-penetrating Peptide Conjugated and Doxorubicin Loaded T1-T2 Dual Mode MRI Contrast Agents Nanoparticles for Tumor Theranostics |
URI | https://www.proquest.com/docview/1983255941 https://pubmed.ncbi.nlm.nih.gov/PMC5743462 |
Volume | 8 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1LT8QgECY-LnowPuM7mHhlXVpa4GSMj6hxjTHdxNsGCviIgu62id794Q7dmrjGg9c2DGQY4Jth-AahfaukcZlwBGxXEjAKSnSZKGI1YBPrKE_L-FC4d52f99nlXXY3hb7rd7YKHP3p2sV6Uv3hc-f97eMQFjzg1w4HPHNQPfjQSWJm4TSahROJxwXaa2F-syODkySbGh9gwAKGxbpjptJfzSdQ5mSO5I9D52wRLbRoER-Np3cJTVm_jOZ_cAiuoM-ifglDAoO2DQOuv8c3MVPFWHwc_FMdw2QGK2_wSXgPw1rHq3R8FZSBzwUlRYJPaugjFkXDvduL2AoEjSp8FF9djTDsv-BYt_lzGDAubnrERXy55UPD87yK-menxfE5aUsrkKeUZRUxNOOpyrl1UvDUKSsB18lSZzkT1OYi4UZpl5RGGCWt6Lqus5KalEkTGbK66Rqa8cHbdYSpkCBFCyadZFmZanCAlEwcCGIZ18kG2vtW6gBMN95HKG9DPRpQCdsJeDSMbiA-oe3B65hqYxDJryf_-MeHhgQ7A-jD8mTzH9K30BzAHDEOnGyjmWpY2x2AEpXebexkt4nxfAHBLc3l |
linkProvider | Scholars Portal |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Tumor-penetrating+Peptide+Conjugated+and+Doxorubicin+Loaded+T1-T2+Dual+Mode+MRI+Contrast+Agents+Nanoparticles+for+Tumor+Theranostics&rft.jtitle=Theranostics&rft.au=Gao%2C+Lipeng&rft.au=Yu%2C+Jing&rft.au=Liu%2C+Yang&rft.au=Zhou%2C+Jinge&rft.date=2018-01-01&rft.issn=1838-7640&rft.eissn=1838-7640&rft.volume=8&rft.issue=1&rft.spage=92&rft_id=info:doi/10.7150%2Fthno.21074&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1838-7640&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1838-7640&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1838-7640&client=summon |